Reports
Reports
Sale
The rheumatoid arthritis therapeutics market was valued at USD 29506.4 million in 2023, driven by the increasing prevalence of rheumatoid arthritis across the globe. The market is expected to grow at a CAGR of 4.60% during the forecast period of 2024-2032, with the values likely to rise from USD 30.864 billion in 2024 to USD 44228.4 million by 2032.
Rheumatoid arthritis (RA) is an auto-immune disorder, a condition in which a person's immune system identifies one's cellular and organ makeup as antigenic entities, resulting in the synthesis of antibodies against one's own body. The disease tends to attack the linings of the joints leading to bone abrasion, joint inflammation, and severe pain. If left untreated, the disease could spread across various organs, which initially affect the joints of fingers and toes. A surge in obesity rates, increasing awareness concerning rheumatic disorders, and the rising geriatric population have significantly contributed to the market growth. Additionally, the rise in generic drug approvals and growth in clinical trials reflects the ongoing expansion of the market.
Growing Prevalence of Rheumatoid Arthritis Drives the Market Demand
A significant driver in the market includes the growing prevalence of the disease. Recent data reveals that around 1.5 million people in the United States are affected by rheumatoid arthritis. Moreover, females are reported to be nearly three times more likely to develop the autoimmune condition as compared to males. Research has shown that early treatment can put the disease into remission, reflecting the importance of effective therapeutics to manage the condition. Thus, with the rising cases of the disease, the market demand for these drugs is expected to witness a rise. Further, the increasing aging population which is at a higher risk of developing the disorder is poised to influence the market landscape.
Rising Entry of Generic Drugs Supports the Market Expansion
In August 2023, an Indian multinational pharmaceutical company Zydus Lifesciences Limited received the United States US Food and Drug Administration's (FDA) approval to manufacture and market its generic Indomethacin suppositories (50 mg strength), a non-steroidal and anti-inflammatory drug used for the treatment of moderate to severe rheumatoid arthritis. The FDA also granted a 180-day competitive generic therapy (CGT) exclusivity to market the generic treatment drug as it deemed there is inadequate generic competition for the drug in the United States market. The rise in the approval of generic therapeutics indicated for rheumatoid arthritis is likely to improve the accessibility of treatment alternatives to the growing patient pool, which is projected to bolster the market growth in the forecast period.
Surge in Clinical Trials of Novel Therapies to Meet the Rising Rheumatoid Arthritis Therapeutics Market Demand
One of the major market trends is the growth in clinical trials of new and advanced rheumatoid arthritis medications which are anticipated to enhance patient outcomes and stimulate market expansion. In October 2023, a United States-based biotechnology company Rise Therapeutics revealed that the regulatory agency FDA has accepted its investigational new drug (IND) application that will allow initiation of the Phase I clinical trial of R-2487 intended for the treatment of rheumatoid arthritis. In the single and repeat-dose clinical study enrolling 36 subjects, the cellular immunotherapy R-2487 will be assessed for tolerability, drug exposure, safety, and clinical activity. It is reported that the clinical activity of R-2487 will be evaluated by measuring improvement in rheumatoid arthritis disease severity and other biomarkers. The development of such oral immunotherapy treatments that can facilitate ease of delivery of protein-based biologics therapy and are available at reduced costs are projected to positively impact the market dynamics.
Rising Preference for Combination Therapies is Projected to Boost Rheumatoid Arthritis Therapeutics Market Size
Treatments for rheumatoid arthritis manage inflammation in the affected patients and can ease associated symptoms like pain and stiffness. However, sometimes a single drug is not sufficient to treat this autoimmune disease. In such cases, patients are prescribed with more than one drug to effectively control the symptoms. For example, a treatment that combines ethotrexate with leflunomide or methotrexate with sulfasalazine is reported to be the most effective two-drug combinations of conventional disease-modifying antirheumatic drugs (DMARDs) . The rising demand for combination therapies due to their ability to provide better clinical benefits is anticipated to fuel the market size.
Advances in Personalized Medicine is Likely to Elevate Rheumatoid Arthritis Therapeutics Market Value
The rising advancements in personalized treatment approaches supported by robust research initiatives is resulting in tailored therapies that can improve patient outcomes. Biomarkers are increasingly employed as key tools in the development of personalized medicine towards rheumatoid arthritis to accurately predict the patient’s disease phenotype and response to treatment. Further, the growing innovation in omic technologies and clinical study design is expected to accelerate rheumatoid biomarker discovery, which is likely to amplify the demand for precision medicine, thereby stimulating market growth.
Market Breakup by Product Type
Market Breakup by Sales Type
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by End User
Market Breakup by Region
Market Segmentation Based on Product Type is Poised to Propel Market Growth
The market segmentation by product type includes biologics and non-biologics. Biologics include advanced drugs such as tumor necrosis factor (TNF) inhibitors and interleukin inhibitors. These medications target specific parts of the immune system responsible for inflammation in rheumatoid arthritis. Non-biologics are further subdivided into non-steroidal anti-inflammatory drugs (NSAIDs), synthetic disease-modifying antirheumatic drugs (SDMARDs) like methotrexate, and other medications including corticosteroids that help manage symptoms or certain complications. There is a growing demand for biologics due to their ability to prevent long-term disability associated with the disease is likely to augment the rheumatoid arthritis therapeutics market demand.
Prescription and Over-the-Counter Rheumatoid Arthritis Therapeutics are Witnessing Market Demand
Based on the sales type, the market comprises prescription, and over-the-counter rheumatoid arthritis therapeutics, among others. Prescription drugs hold a significant share, including majority of rheumatoid arthritis therapies that require medical oversight due to their potential side effects. Over-the-counter (OTC) drugs, mainly some non-steroidal anti-inflammatory (NSAIDs), are available without a prescription to manage pain and inflammation. Advil and Aleve are some examples of widely used rheumatoid arthritis drugs that are sold over-the-counter.
The market is witnessing colossal growth in United States due to the highest reported disease cases. Moreover, the increasing awareness and health consciousness among people have significantly contributed to the dominant share of the regional market. Also, the increasing budget allocation in the arena of rheumatoid arthritis therapeutics equally raises its market value.
EU-4 and the United Kingdom has seen significant propellants in the form of innovative drugs, advanced healthcare alternatives to grapple with the disease, and an increment in cases. In the Asia Pacific region, Japan, and India’s market growth is catalyzed by the improvement in healthcare infrastructure, increasing awareness, and growing adoption of biologics.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Drug Class |
|
Breakup by Sales Channel |
|
Breakup by Route of Administration |
|
Breakup by Distribution Channel |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Rheumatoid Arthritis Therapeutics Market Overview - 8 Major Markets
3.1 Rheumatoid Arthritis Therapeutics Market Historical Value (2017-2023)
3.2 Rheumatoid Arthritis Therapeutics Market Forecast Value (2024-2032)
4 Rheumatoid Arthritis – Disease Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Rheumatoid Arthritis Epidemiology Analysis – 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Rheumatoid Arthritis Epidemiology Scenario and Forecast (2017-2032)
6.3 EU-4 and United Kingdom Rheumatoid Arthritis Epidemiology Scenario and Forecast (2017-2032)
6.3.1 Germany Rheumatoid Arthritis Epidemiology Scenario and Forecast (2017-2032)
6.3.2 France Rheumatoid Arthritis Epidemiology Scenario and Forecast (2017-2032)
6.3.3 Italy Rheumatoid Arthritis Epidemiology Scenario and Forecast (2017-2032)
6.3.4 Spain Rheumatoid Arthritis Epidemiology Scenario and Forecast (2017-2032)
6.3.5 United Kingdom Rheumatoid Arthritis Epidemiology Scenario and Forecast (2017-2032)
6.4 Japan Rheumatoid Arthritis Epidemiology Scenario and Forecast (2017-2032)
6.5 India Rheumatoid Arthritis Epidemiology Scenario and Forecast (2017-2032)
7 Rheumatoid Arthritis Therapeutics Market Landscape* - 8 Major Markets
7.1 Rheumatoid Arthritis Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Rheumatoid Arthritis Therapeutics: Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by Sales Channel
7.2.3 Analysis by Route of Administration
8 Rheumatoid Arthritis Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Rheumatoid Arthritis Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Rheumatoid Arthritis Therapeutics Market Segmentation - 8 Major Markets
11.1 Rheumatoid Arthritis Therapeutics Market by Drug Class
11.1.1 Market Overview
11.1.2 Biologics
11.1.3 Non-Biologics
11.1.3.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
11.1.3.2 Disease-Modifying Antirheumatic Drugs (DMARDs)
11.1.3.3 Others
11.2 Rheumatoid Arthritis Therapeutics Market by Sales Channel
11.2.1 Market Overview
11.2.2 Prescription
11.2.3 Over The Counter (OTC)
11.2.4 Others
11.3 Rheumatoid Arthritis Therapeutics Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Parenteral
11.4 Rheumatoid Arthritis Therapeutics Market by Distribution Channel
11.4.1 Market Overview
11.4.2 Hospital Pharmacy
11.4.3 Retail Pharmacy
11.4.4 Online
11.5 Rheumatoid Arthritis Therapeutics Market by End User
11.5.1 Market Overview
11.5.2 Hospitals & Clinics
11.5.3 Research and Academic Laboratories
11.5.4 Others
11.6 Rheumatoid Arthritis Therapeutics Market by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
11.6.5 India
12 United States Rheumatoid Arthritis Therapeutics Market
12.1 United States Rheumatoid Arthritis Therapeutics Market Historical Value (2017-2023)
12.2 United States Rheumatoid Arthritis Therapeutics Market Forecast Value (2024-2032)
12.3 United States Rheumatoid Arthritis Therapeutics Market by Drug Class
12.4 United States Rheumatoid Arthritis Therapeutics Market by Sales Channel
13 EU4 and United Kingdom Rheumatoid Arthritis Therapeutics Market
13.1 EU4 and United Kingdom Rheumatoid Arthritis Therapeutics Market Historical Value (2017-2023)
13.2 EU4 and United Kingdom Rheumatoid Arthritis Therapeutics Market Forecast Value (2024-2032)
13.3 EU4 and United Kingdom Rheumatoid Arthritis Therapeutics Market by Drug Class
13.4 EU4 and United Kingdom Rheumatoid Arthritis Therapeutics Market by Sales Channel
14 Japan Rheumatoid Arthritis Therapeutics Market
14.1 Japan Rheumatoid Arthritis Therapeutics Market Historical Value (2017-2023)
14.2 Japan Rheumatoid Arthritis Therapeutics Market Forecast Value (2024-2032)
14.3 Japan Rheumatoid Arthritis Therapeutics Market by Drug Class
14.4 Japan Rheumatoid Arthritis Therapeutics Market by Sales Channel
15 India Rheumatoid Arthritis Therapeutics Market
15.1 India Rheumatoid Arthritis Therapeutics Market Historical Value (2017-2023)
15.2 India Rheumatoid Arthritis Therapeutics Market Forecast Value (2024-2032)
15.3 India Rheumatoid Arthritis Therapeutics Market by Drug Class
15.4 India Rheumatoid Arthritis Therapeutics Market by Sales Channel
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 India CDSCO
16.1.4 Japan PMDA
16.1.5 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Market Share of Top 5 Companies
22.2 Pfizer Inc.
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 Amgen Inc.
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Bristol-Myers Squibb Company
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 F. Hoffmann-La Roche Ltd
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Boehringer Ingelheim GmbH
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Novartis International AG
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Regeneron Pharmaceuticals, Inc.
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 AbbVie.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Eli Lilly and Company
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 UCB S.A.
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
22.12 Gilead Sciences, Inc.
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisitions
22.12.5 Certifications
22.13 Celgene Corporation
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisitions
22.13.5 Certifications
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.